Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that the Company's partner, Moberg Pharma AB, ("Moberg Pharma") has submitted a regulatory filing for the next...

Demonstrated growth in FY 2021 as EBITDA increased 46% to $11.8 million Disciplined cost structure led to an 18% reduction in SG&A 81% increase in EPS to $0.29 in FY2021 Strengthened cash flow...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its financial and operating results for the three and twelve months ended December 31, 2021...

Royalty agreement granting Sun Pharmaceutical Industries Inc. exclusive right to market, sell and distribute Absorica, Absorica AG and Absorica LD in the U.S. extended through December 31, 2026...

Revenue for nine months ended September 30, 2021increases 4.1% to $16.1 million Adjusted EBITDA1 for nine months ended September 30, 2021 increases to $9.8 million Basic EPS for the nine months ended

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced that it will release its Q3 2021 financial results on Thursday, November 11, 2021. The company will hold a...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of Cipher's intention to renew...

Revenue increases 30% to $6.1 million, Adjusted EBITDA2 increases 40% to $4.1 million EPS increases 450% to $0.11 (CDN$0.141) Epuris revenue grows 63%, Absorica revenue grows 25% All figures in...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or "the Company") today announced it will release its Q2 2021 financial results on Thursday, August 12, 2021. The company will hold a conference...

Cipher Pharmaceuticals Inc. (TSX: CPH) ("Cipher" or the "Company") today announced the voting results for the election of directors at its Annual Meeting of Shareholders held earlier today. A...